Augmented glaucoma system improves IOP in youngsters
September 13, 2025
1 min learn
Key takeaways:
- Ologen mitigates the hypertension section.
- Augmented units decreased strain and the variety of glaucoma drugs.
COPENHAGEN, Denmark— Glaucoma units augmented with Ologen helped scale back IOP and the variety of drugs utilized in pediatric sufferers, in accordance with a research.
In a presentation on the European Society of Cataract and Refractive Surgeons assembly, Brenda L. Bohnsack, MD, PhD, mentioned Ologen (Aeon Astron) is positioned on the again of an Ahmed glaucoma valve (New World Medical) to assist forestall scarring.
Information had been derived from Bohnsack, B. Ologen-augmentation of Ahmed glaucoma units (OAGD) in pediatric glaucoma: 3-6 yr follow-up. Introduced at: European Society of Cataract and Refractive Surgeons assembly; Sept. 12-16, 2025; Copenhagen, Denmark.
“It is integrating into the tissues and selling nonscarring wound therapeutic,” she mentioned. “It prevents the group of fibroblasts and thereby prevents scars. It has been utilized in glaucoma surgical procedure and been printed on for about 10 to fifteen years now, particularly in trabeculectomy plus minus antifibrotics, in addition to in bleb revision for trabeculectomies.”
Bohnsack and colleagues analyzed information from 40 eyes from 28 sufferers who underwent Ologen-augmented system implantation. At baseline, sufferers had a median IOP of 29.6 mm Hg, they had been on a median of two.7 glaucoma drugs, and 38 eyes of 27 sufferers had been on glaucoma treatment. The median age on the time of surgical procedure was 2.6 years, in accordance with the research.
Brenda L. Bohnsack
After the ultimate follow-up, which occurred at a median of three.6 years, sufferers had a median IOP of 14.1 mm Hg and had been on a median of 0.5 glaucoma drugs. Moreover, solely 8 eyes from 6 sufferers had been on any glaucoma treatment (P .0001).
Bohnsack mentioned the process’s survival charges had been promising at 1 to three years (75%-95%), however declined in years 4 to five (57%-76%).
“More often than not, failure was because of bleb encapsulation,” she mentioned. “One factor that was fascinating was that Ologen-augmentation in children appears to do higher than in adults, and we don’t fully perceive that impact. We nonetheless must see what longer-term outcomes there are with a larger variety of eyes.”
